Aligos Therapeutics Inc (STU:5WK0)
€ 11.7 0 (0%) Market Cap: 28.89 Mil Enterprise Value: -49.00 Mil PE Ratio: 0 PB Ratio: 0.45 GF Score: 48/100

Aligos Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 11, 2021 / 08:40PM GMT
Eric William Joseph
JPMorgan Chase & Co, Research Division - VP & Senior Analyst

Thanks again for joining us for the annual JPMorgan Healthcare Conference. I'm Eric Joseph, senior biotech analyst at the firm. Our next presenting company is Aligos Therapeutics, and it's my pleasure to welcome and introduce Lawrence Blatt to tell us a little bit about the company.

Just a note before I hand it over, there will be a Q&A session after the presentation. So please do feel free to submit questions via the portal by clicking the Ask a Question button, and I'll ask on your behalf.

With that, Lawrence, thanks again for sharing some of your time with us.

Lawrence M. Blatt
Aligos Therapeutics, Inc. - CEO & Director

Thank you, Eric, and thanks for everybody for coming to this portion of the conference. I will be using the slide deck that is available to you on the JPMorgan website, and I'll call out the slides as I go.

We are Aligos Therapeutics. And if we could move to Slide 3, you can see that our mission for our company is

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot